CompletedPhase 3

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

United States204 participantsStarted 2023-03-10

Plain-language summary

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Vulnerable populations according to article L.1121-6 of the French Public Health Code.
✕. Adults under legal protection or who are unable to express their consent per article L.1121-8 of the French Public Health Code.
✕. Individuals not affiliated with the social security system.

WI-NRS4 Response at Week 12

Timeframe: Baseline; Week 12

NCT IDNCT05755438

SponsorIncyte Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-10-07

Results submitted2025-09-29